Effect of alirocumab on cataracts in patients with acute coronary syndromes (vol 23, 279, 2023)

Suc, G.; Schwartz, G.G.; Goodman, S.G.; Jukema, J.W.; Manvelian, G.; Poulouin, Y.; ... ; ODYSSEY OUTCOMES Investigators

BMC Ophthalmology

CORRECTION

Open Access

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes

Gaspard Suc[1,2], Gregory G. Schwartz[3], Shaun G. Goodman[4,5], J. Wouter Jukema[6,7], Garen Manvelian[8], Yann Poulouin[9], Robert Pordy[8], Michel Scemama[10], Michael Szarek[11,12], Ph.Gabriel Steg[1,2,13,14,15*] and ODYSSEY OUTCOMES Investigators[1,2,3,13,14]

Correction: BMC Ophthalmol 23, 279 (2023)
https://doi.org/10.1186/s12886–023-03012-1

After publication of the original article [1], the author group noticed a calculation error that has affected Tables 3 and 5 as well as the second paragraph of the Results section in page 4.

The original article has been updated and the correct values are also given below in bold.

The original article can be found online at https://doi.org/10.1186/s12886-023-03012-1.

*Correspondence:
Ph.Gabriel Steg
gabriel.steg@aphp.fr
[1] Université Paris-Cité, INSERM_U1148/LVTS, Paris, France
[2] Assistance Publique-Hôpitaux de Paris, HôpitalBichat, Paris, France
[3] Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA
[4] Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada
[5] St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
[6] Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
[7] Netherlands Heart Institute, Utrecht, the Netherlands
[8] Regeneron Pharmaceuticals, Tarrytown, NY, USA
[9] IT&M Stats, Neuilly-Sur-Seine, France
[10] Sanofi, Chilly-Mazarin, France
[11] Downstate School of Public Health, State University of New York, Brooklyn, NY, USA
[12] CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA
[13] Institut Universitaire de France, Paris, France
[14] FACT (French Alliance for Cardiovascular Trials), INSERM U-1148, Paris, France
[15] Département de Cardiologie, AP-HP Hôpital Bichat, 46 Rue Henri Huchard, Paris 75018, France

Table 3 Baseline lipid parameters in patients on alirocumab with ≥ 2 consecutive LDL-C values < 25 mg/dL and propensity score-matched patients on placebo

	All (*N* = 8610)	Alirocumab (*N* = 4305)	Placebo (*N* = 4305)
LDL-C, mmol/L	2.1 ± 0.6	2.1 ± 0.6	2.16 ± 0.
Non-HDL-C, mmol/L	2.9 ± 0.7	2.9 ± 0.7	2.9 ± 0.7
Total cholesterol, mmol/L	4.0 ± 0.8	4.0 ± 0.8	4.0 ± 0.8
HDL-C, mmol/L	1.1 ± 0.3	1.1 ± 0.3	1.1 ± 0.3
Fasting triglycerides, mmol/L	1.8 ± 1.0	1.8 ± 1.0	1.8 ± 1.1
Lipoprotein(a), mg/dL	**28.6 ± 33.1**	**28.7 ± 33.3**	**28.7 ± 33.2**
Apolipoprotein B, mg/dL	**77.6 ± 17.3**	**78.1 ± 17.5**	**77.9 ± 17.4**
Apolipoprotein A1, mg/dL	**131.6 ± 23.0**	**131.2 ± 22.5**	**131.4 ± 22.7**
Apolipoprotein B/Apolipoprotein A1 ratio[a]	0.61 ± 0.2	0.61 ± 0.2	0.61 ± 0.2
Total cholesterol/HDL-C ratio[a]	3.8 ± 1.0	3.8 ± 1.0	3.8 ± 1.0

Data are presented as mean ± SD

HDL-C high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *Q* quartile, *SD* standard deviation

[a] Ratios were only calculated if the 2 samples were collected at the same visit

Table 5 Baseline lipid parameters in patients on alirocumab with ≥ 2 consecutive LDL-C values < 15 mg/dL and propensity score-matched patients on placebo

	All (*N* = 3128)	Alirocumab (*N* = 782)	Placebo (*N* = 2346)
LDL-C, mmol/L	2.0 ± 0.5	2.0 ± 0.6	2.0 ± 0.5
Non-HDL-C, mmol/L	2.8 ± 0.7	2.8 ± 0.7	2.8 ± 0.6
Total cholesterol, mmol/L	3.9 ± 0.7	3.9 ± 0.8	3.9 ± 0.7
HDL-C, mmol/L	1.1 ± 0.3	1.1 ± 0.3	1.1 ± 0.3
Fasting triglycerides, mmol/L	1.8 ± 1.1	1.8 ± 0.9	1.8 ± 1.1
Lipoprotein(a), mg/dL	**18.8 ± 23.1**	**19.3 ± 22.4**	**18.7 ± 23.3**
Apolipoprotein B, mg/dL	**75.4 ± 16.0**	**76.0 ± 17.5**	**75.2 ± 15.4**
Apolipoprotein A1, mg/dL	**129.9 ± 22.9**	**129.2 ± 22.3**	**130.1 ± 23.1**
Apolipoprotein B/Apolipoprotein A1 ratio[a]	0.6 ± 0.2	0.6 ± 0.2	0.6 ± 0.2
Total cholesterol/HDL-C ratio[a]	3.7 ± 1.0	3.7 ± 0.9	3.7 ± 1.0

Data are presented as mean ± SD

HDL-C high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *Q* quartile, *SD* standard deviation.

[a] Ratios were only calculated if the 2 samples were collected at the same visit.

The second paragraph in page 4 should read:

A total of 4305 patients in the alirocumab group had ≥ 2 consecutive LDL-C values < 25 mg/dL (0.65 mmol/L) and were matched to 4305 patients from the placebo group with similar baseline characteristics (Tables 2 and 3). Baseline characteristics of these patients included mean age 59 years, male sex (81%), diabetes (33%); and mean body mass index 28.3 kg/m2, LDL-C 2.1 mmol/L, lipoprotein (a) **28.6** mg/dL, and apolipoprotein A1 **131.6** mg/dL. A total of 782 patients in the alirocumab group had ≥ 2 consecutive LDL-C values < 15 mg/dL (0.39 mmol/L) and were matched to 2346 patients from the placebo group with similar baseline characteristics (Tables 4 and 5). Baseline characteristics of these patients included mean age 59 years, male sex (81%), diabetes (33%); and mean body mass index 27.3 kg/m2, LDL-C 2.0 mmol/L, lipoprotein (a) **18.8** mg/dL, and apolipoprotein A1 **129.9** mg/dL.

Published online: 06 July 2023

Reference

1. Suc G, Schwartz GG, Goodman SG, et al. Effect of alirocumab on cataracts in patients with acute coronary syndromes. BMC Ophthalmol. 2023;23:279. https://doi.org/10.1186/s12886-023-03012-1.